Phase II study in which all patients undergoing IRE for the treatment of locally advanced pancreatic carcinoma will receive either FOLFIRINOX or gemcitabine as peri-ablation treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
greater than or equal to 18 years of age
diagnosed with stage III pancreatic cancer
tumor is measurable
GFR \> mL/min/1.73m2
willing and able to comply with protocol requirements
AST/ALT \>3 times upper limit of normal
stable surgical post-operative course as defined by operative surgeon
You may not be if
participating in another clinical trial for the treatment of cancer at the time of screening
pregnant or currently breast feeding
have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure
have non-removable implants with metal parts within 1 cm of the target lesion
had a myocardial infarction within 3 months prior to enrollment
Clareo Health | Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
